معرفی
Professor Adam Walker serves as Chair of Pharmacological Sciences at the Sydney Pharmacy School within the Faculty of Medicine and Health at the University of Sydney. He maintains active research affiliations with the Charles Perkins Centre, focusing on interdisciplinary approaches to neurodegenerative conditions.
His research program centers on TDP-43 proteinopathies in Motor Neuron Disease (ALS) and dementia, utilizing animal models, cellular/molecular techniques, and pathogenesis studies. Key interests include glymphatic system dysfunction, neuroinflammatory mechanisms, and molecular drivers of neurodegeneration, with emphasis on translating findings into therapeutic strategies.
Analysis of his 2025 publications reveals concentrated investigation into TDP-43 pathology across multiple dimensions: glymphatic impairment (Zamani et al.), IL-6 mediated neuroinflammation (Risby-Jones et al.), phosphorylation mechanisms (Kellett et al.), proteomic interactome mapping (Cheng et al.), and therapeutic development pathways (San Gil et al.). This cohesive body of work demonstrates a translational research trajectory targeting disease-modifying interventions for ALS and related dementias.
Scientific awards:
- No awards explicitly documented in current profile
Walker currently supervises PhD candidate Natalie CLUBLEY on TDP-43 dysfunction mechanisms in MND/dementia models. His active funding includes a 2025 FightMND Drug Development Grant for "Upstream Protein Clearance Pathway Activators for MND Treatment" and a 2024 FMH Start-up Scheme grant supporting new academic research infrastructure.
As a Charles Perkins Centre member, he collaborates within a multidisciplinary ecosystem addressing complex health challenges through integrated basic and clinical science approaches, particularly leveraging the Centre's strengths in neurodegenerative disease research.
